Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US – a $3.5 billion facility in Lehigh Valley, Pennsylvania. The company said the site will ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...

Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...

Pfizer acquired Tukysa as part of its $43 billion takeover of Seagen in 2023, three years after the drug first reached the US ...

The Nobel Prize in Chemistry 2026 has been awarded to two scientists - Henri B Kagan and Kensō Soai – for discoveries on ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...

Wegovy has since been joined in the UK market by Eli Lilly's oral GLP-1 agonist Foundayo (orforglipron), which was approved by the MHRA in August. Neither product is covered by the NHS, but can be ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...